EMEA-003466-PIP01-23 - paediatric investigation plan
Amlodipine
Atorvastatin
Candesartan
PIPHuman
Key facts
- Active Substance
- Amlodipine
- Atorvastatin
- Candesartan
- Therapeutic area
- Cardiac disorders
- Decision number
- P/0465/2023
- PIP number
- EMEA-003466-PIP01-23
- Pharmaceutical form(s)
- Tablet
- Condition(s) / indication(s)
- Prevention of cardiovascular events
- Route(s) of administration
- Oral use
- Contact for public enquiries
Teva B.V.
Email: MedAffGenTevaEurope@tevapharm.com
Tel. +385 13722001- Decision type
- W: decision granting a waiver in all age groups for all conditions or indications
- Decision date